文献一覧: Tomofumi Takaya (著者)

38 0 0 0 OA JCS 2022 Guideline on Perioperative Cardiovascular Assessment and Management for Non-Cardiac Surgery

著者: Eiji Hiraoka Kengo Tanabe Shinichiro Izuta Tadao Kubota Shun Kohsaka Amane Kozuki Kazuhiro Satomi Hiroki Shiomi Toshiro Shinke Toshiyuki Nagai Susumu Manabe Yasuhide Mochizuki Taku Inohara Mitsuhiko Ota Tetsuma Kawaji Yutaka Kondo Yumiko Shimada Yohei Sotomi Tomofumi Takaya Atsushi Tada Tomohiko Taniguchi Kazuya Nagao Kenichi Nakazono Yukiko Nakano Kazuhiko Nakayama Yuichiro Matsuo Takashi Miyamoto Yoshinao Yazaki Kazuyuki Yahagi Takuya Yoshida Kohei Wakabayashi Hideki Ishii Minoru Ono Akihiro Kishida Takeshi Kimura Tetsuro Sakai Yoshihiro Morino on behalf of the Japanese Society Joint Working Group
出版者: The Japanese Circulation Society
雑誌: Circulation Journal (ISSN:13469843)
巻号頁・発行日: pp.CJ-22-0609, (Released:2023-08-10)
参考文献数: 439
被引用文献数: 7

2023-08-26 06:37:54
38 + 98 Twitter

10 0 0 0 OA Longitudinal Stent Elongation Due to Inappropriate Post-Dilatation ― Insight From a Bench Test ―

著者: Hiroyuki Yamamoto Shinsuke Nakano Takayuki Saito Tomofumi Takaya
出版者: The Japanese Circulation Society
雑誌: Circulation Reports (ISSN:24340790)
巻号頁・発行日: pp.CR-23-0026, (Released:2023-04-04)
参考文献数: 1

2023-06-26 19:53:49
10 + 40 Twitter

7 0 0 0 OA Isolated Renal Arteritis With Infarction Identified After SARS-CoV-2 Vaccine

著者: Akiko Masumoto Hiroyuki Yamamoto Yasuyo Taniguchi Hiroya Kawai Tomofumi Takaya
出版者: The Japanese Circulation Society
雑誌: Circulation Journal (ISSN:13469843)
巻号頁・発行日: pp.CJ-21-1050, (Released:2022-01-29)
参考文献数: 3
被引用文献数: 2

2022-03-05 19:15:06
7 + 10 Twitter

6 0 0 0 OA Fever-Related Ventricular Fibrillation ― Potential Adverse Effect of SARS-CoV-2 Vaccination in Patients With Brugada Syndrome ―

著者: Tatsuya Kokawa Hiroyuki Yamamoto Mitsuaki Itoh Akira Shimane Hiroya Kawai Tomofumi Takaya
出版者: The Japanese Circulation Society
雑誌: Circulation Journal (ISSN:13469843)
巻号頁・発行日: vol.86, no.3, pp.474, 2022-02-25 (Released:2022-02-25)
参考文献数: 3
被引用文献数: 6

2022-06-15 06:46:46
6 + 9 Twitter

6 0 0 0 OA Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease

著者: Takahiro Sawada Kenzo Uzu Naoko Hashimoto Tetsuari Onishi Tomofumi Takaya Akira Shimane Yasuyo Taniguchi Yoshinori Yasaka Takeshi Ohara Hiroya Kawai
出版者: Japan Atherosclerosis Society
雑誌: Journal of Atherosclerosis and Thrombosis (ISSN:13403478)
巻号頁・発行日: pp.50807, (Released:2019-10-18)
参考文献数: 41
被引用文献数: 28

Aim: So far, the mechanisms behind the cardiovascular benefits of sodium/glucose cotransporter 2 (SGLT2) inhibitors have not been fully clarified. Methods: In order to evaluate the effects of SGLT2 inhibitors on systemic hemodynamics, glucose metabolism, lipid profile, and endothelial function, 50 diabetic patients with established coronary artery disease (CAD) were included in this analysis and were given empagliflozin 10 mg/d. Cookie meal testing (carbohydrates: 75 g, fats: 28.5 g), endothelial function testing using flow-mediated dilatation (FMD), and body composition evaluation were performed before and after six months of treatment. Changes in %FMD between the treatment periods and its association with metabolic biomarkers were evaluated. Results: After six months of treatment, the body weight and body fat percentage decreased significantly, while the body muscle percentage increased significantly. The hemoglobin A1c level and fasting and postprandial plasma glucose levels were significantly decreased with treatment. Postprandial insulin secretion was also significantly suppressed and the insulin resistance index was significantly decreased. Furthermore, the fasting and postprandial triglyceride (TG) levels decreased significantly, while total ketone bodies increased significantly after the six-month treatment. While the plasma brain natriuretic peptide level was not changed, the C-reactive protein level was decreased and FMD was significantly improved after the six-month treatment. Multiple regression analysis showed that the strongest predictive factor of FMD improvement is change in the plasma TG levels. Conclusion: SGLT2 inhibitors improve multiple metabolic parameters. Of these, a reduction in plasma TGs was strongly associated with endothelial function recovery in diabetic patients with CAD, and this reduction may be related to the cardiovascular benefits of SGLT2 inhibitors.